XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Business segment information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Segment Reporting [Abstract] |
Schedule Of Net Sales by Reporting Segment | The table below present net sales, which includes product sales and marketing service fees, by reporting segment:
|  | Three Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
BioStim |  | $ | 48,211 |  |  | $ | 47,174 |  |  |  | 2.2 | %
Spine Fixation |  |  | 23,880 |  |  |  | 21,360 |  |  |  | 11.8 | %
Biologics |  |  | 14,668 |  |  |  | 15,661 |  |  |  | -6.3 | %
Extremity Fixation |  |  | 24,788 |  |  |  | 24,747 |  |  |  | 0.2 | %
Net sales |  | $ | 111,547 |  |  | $ | 108,942 |  |  |  | 2.4 | %
|  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
BioStim |  | $ | 94,374 |  |  | $ | 91,713 |  |  |  | 2.9 | %
Spine Fixation |  |  | 44,587 |  |  |  | 40,627 |  |  |  | 9.7 | %
Biologics |  |  | 29,003 |  |  |  | 30,648 |  |  |  | -5.4 | %
Extremity Fixation |  |  | 52,292 |  |  |  | 48,692 |  |  |  | 7.4 | %
Net sales |  | $ | 220,256 |  |  | $ | 211,680 |  |  |  | 4.1 | %
Summary of Non-GAAP Net Margin by Reporting Segment | The table below presents non-GAAP net margin by reporting segment:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
BioStim |  | $ | 21,298 |  |  | $ | 19,469 |  |  | $ | 40,244 |  |  | $ | 36,602 |
Spine Fixation |  |  | 2,887 |  |  |  | 2,696 |  |  |  | 4,148 |  |  |  | 4,703 |
Biologics |  |  | 6,247 |  |  |  | 6,470 |  |  |  | 12,327 |  |  |  | 12,641 |
Extremity Fixation |  |  | 7,002 |  |  |  | 6,766 |  |  |  | 15,160 |  |  |  | 13,178 |
Corporate |  |  | (251 | ) |  |  | (107 | ) |  |  | (402 | ) |  |  | (205 | )
Non-GAAP net margin |  | $ | 37,183 |  |  | $ | 35,294 |  |  | $ | 71,477 |  |  | $ | 66,919 |
General and administrative |  |  | 22,268 |  |  |  | 20,409 |  |  |  | 41,752 |  |  |  | 38,691 |
Research and development |  |  | 7,891 |  |  |  | 6,887 |  |  |  | 14,828 |  |  |  | 14,311 |
Operating income |  | $ | 7,024 |  |  | $ | 7,998 |  |  | $ | 14,897 |  |  | $ | 13,917 |
Interest income (expense), net |  |  | (251 | ) |  |  | 76 |  |  |  | (434 | ) |  |  | 121 |
Other income (expense), net |  |  | (4,752 | ) |  |  | 585 |  |  |  | (1,840 | ) |  |  | (3,763 | )
Income before income taxes |  | $ | 2,021 |  |  | $ | 8,659 |  |  | $ | 12,623 |  |  | $ | 10,275 |
Summary of Net Sales by Geographic Destination for Each Reporting Unit | Geographical information The table below present net sales by geographic destination for each reporting unit and for the consolidated Company:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
BioStim |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 48,202 |  |  | $ | 47,162 |  |  | $ | 94,339 |  |  | $ | 91,701 |
International |  |  | 9 |  |  |  | 12 |  |  |  | 35 |  |  |  | 12 |
Total BioStim |  |  | 48,211 |  |  |  | 47,174 |  |  |  | 94,374 |  |  |  | 91,713 |
Spine Fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 18,853 |  |  |  | 18,050 |  |  |  | 36,432 |  |  |  | 34,085 |
International |  |  | 5,027 |  |  |  | 3,310 |  |  |  | 8,155 |  |  |  | 6,542 |
Total Spine Fixation |  |  | 23,880 |  |  |  | 21,360 |  |  |  | 44,587 |  |  |  | 40,627 |
Biologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 14,667 |  |  |  | 15,651 |  |  |  | 28,989 |  |  |  | 30,614 |
International |  |  | 1 |  |  |  | 10 |  |  |  | 14 |  |  |  | 34 |
Total Biologics |  |  | 14,668 |  |  |  | 15,661 |  |  |  | 29,003 |  |  |  | 30,648 |
Extremity Fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 7,023 |  |  |  | 6,741 |  |  |  | 13,939 |  |  |  | 13,320 |
International |  |  | 17,765 |  |  |  | 18,006 |  |  |  | 38,353 |  |  |  | 35,372 |
Total Extremity Fixation |  |  | 24,788 |  |  |  | 24,747 |  |  |  | 52,292 |  |  |  | 48,692 |
Consolidated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 88,745 |  |  |  | 87,604 |  |  |  | 173,699 |  |  |  | 169,720 |
International |  |  | 22,802 |  |  |  | 21,338 |  |  |  | 46,557 |  |  |  | 41,960 |
Net sales |  | $ | 111,547 |  |  | $ | 108,942 |  |  | $ | 220,256 |  |  | $ | 211,680 |

X
- Definition Non GAAP net margin by segment reporting. + References No definition available. + Details
Name: | ofix_NonGAAPNetMarginBySegmentReportingTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenues by reporting segment. + References No definition available. + Details
Name: | ofix_ScheduleOfSegmentReportingRevenuesBySegmentTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration